Inventiva’s Lanifibranor and Empagliflozin: A Promising Combination for Metabolic Dysfunction-Associated Steatohepatitis
Daix, France and New York, NY, USA – In a groundbreaking development in the field of metabolic diseases, Inventiva, a clinical-stage biopharmaceutical company, has announced that the results from its Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) have been chosen for an oral plenary presentation at the upcoming Steatotic Liver Disease (SLD) Summit 2025, hosted by the European Association for the Study of the Liver (EASL) in Estoril, Portugal, on January 23-25.
What is Metabolic Dysfunction-Associated Steatohepatitis (MASH)?
MASH, also known as non-alcoholic steatohepatitis (NASH), is a condition characterized by the accumulation of fat in the liver, inflammation, and damage to liver cells. This condition is often associated with obesity, diabetes, and metabolic syndrome. MASH can lead to scarring (cirrhosis) and liver failure if left untreated.
About Lanifibranor and Empagliflozin
Lanifibranor is an oral small molecule therapy developed by Inventiva for the treatment of MASH. It is a selective PPARĪ“ modulator, which aims to improve metabolic dysfunction and reduce inflammation in the liver. Empagliflozin, on the other hand, is an SGLT2 inhibitor, commonly used to treat type 2 diabetes.
The Combination of Lanifibranor and Empagliflozin
The Proof-of-Concept trial investigated the efficacy and safety of this combination therapy in patients with MASH. The results showed that the combination of lanifibranor and empagliflozin led to significant improvements in liver fat reduction, inflammation, and fibrosis compared to placebo. Furthermore, the combination therapy was well-tolerated with a safety profile similar to the individual treatments.
Impact on Individuals
For people living with MASH, this combination therapy could mean a significant improvement in their quality of life. The treatment may help reduce liver damage, prevent progression to cirrhosis, and even potentially reverse some of the damage. This could lead to improved overall health, reduced risk of liver-related complications, and a better prognosis.
Impact on the World
MASH affects millions of people worldwide, and its prevalence is increasing due to the rising obesity and diabetes rates. This combination therapy, if approved, could provide a much-needed treatment option for this large patient population. Moreover, it could potentially reduce the burden on healthcare systems by preventing the progression of MASH to more severe stages, ultimately leading to cost savings and improved patient outcomes.
Conclusion
Inventiva’s Proof-of-Concept trial results, showcasing the potential of lanifibranor in combination with empagliflozin for the treatment of MASH, are an exciting development in the field of metabolic diseases. The positive outcomes of this study could lead to a significant improvement in the lives of millions of people living with MASH. Furthermore, this combination therapy could have a profound impact on healthcare systems worldwide by reducing the burden of managing this condition and potentially preventing its progression to more severe stages. Stay tuned for further updates on this promising therapy.
- Inventiva’s lanifibranor and empagliflozin combination therapy shows promise in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- The Proof-of-Concept trial results have been selected for an oral plenary presentation at the SLD Summit 2025.
- Lanifibranor is a selective PPARĪ“ modulator, while empagliflozin is an SGLT2 inhibitor.
- The combination therapy led to significant improvements in liver fat reduction, inflammation, and fibrosis.
- This therapy could improve the quality of life for people living with MASH and potentially reverse some damage.
- The impact on healthcare systems could be significant, with potential cost savings and improved patient outcomes.
